GlaxoSmithKline Pharmaceuticals Limited has unveiled a leadership transition that shifts the finance helm within the group. Juby Chandy, who has served as Whole-Time Director and Chief Financial Officer, has tendered his resignation, effective at the close of business on March 11, 2026. In a move that keeps him within the GSK ecosystem, Chandy has been appointed as Finance Head for the Asia Pacific region, signaling a regional expansion of his remit within the company.
The development underscores a pivotal moment for GSK India as it navigates leadership changes at the top tier of its finance function. Reassigning a CFO to oversee the Asia Pacific finance agenda points to an emphasis on regional growth and financial leadership across a broad, high-potential footprint for the pharma giant. While the formal handover is in progress, the company has publicly acknowledged Chandy’s tenure and contributions during his time with GSK India, and wishes the organization continued growth and success.
Chandy’s note of gratitude to the Board and Managing Director reflects the cooperative spirit that has guided his tenure. As GSK India works to secure a seamless transition, observers will be watching for who steps into the CFO role, and how the broader executive team aligns with the company’s strategic priorities in India and beyond.